Spots Global Cancer Trial Database for pemigatinib
Every month we try and update this database with for pemigatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | NCT06389799 | Dedifferentiate... | Pemigatinib Retifanlimab | 18 Years - 100 Years | Lund University Hospital | |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | NCT04003623 | Advanced or Met... FGFR Mutations FGFR Translocat... | Pemigatinib | 18 Years - | Incyte Corporation | |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | NCT04088188 | Advanced Cholan... Metastatic Chol... Unresectable Ch... | Cisplatin Gemcitabine Ivosidenib Pemigatinib | 18 Years - | Academic and Community Cancer Research United | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | NCT05267106 | Glioblastoma Adult-type Diff... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations | NCT05651672 | Gastrointestina... | Pemigatinib | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
| A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients | NCT05210946 | Non-Small Cell ... | Pemigatinib | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | NCT04256980 | Cholangiocarcin... | Pemigatinib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | NCT03656536 | Unresectable Ch... Metastatic Chol... | Pemigatinib Gemcitabine Cisplatin | 18 Years - | Incyte Corporation | |
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | NCT04949191 | Advanced Malign... | Pemigatinib Retifanlimab Pembrolizumab | 18 Years - 90 Years | Incyte Corporation | |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | NCT06022289 | Solid Tumor FGF Receptor Ge... FGF Amplificati... FGF Receptor Ge... FGF Receptor Ge... | Pemigatinib | 18 Years - | Tianjin Medical University Second Hospital | |
| Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | NCT06302621 | Advanced Solid ... Unresectable So... Metastatic Soli... Cholangiocarcin... | Afatinib Pemigatinib | 18 Years - | Massachusetts General Hospital | |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | NCT03914794 | Bladder Cancer NMIBC Non-Muscle Inva... Urothelial Carc... | Pemigatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | NCT05565794 | Intrahepatic Ch... FGFR2 Gene Muta... FGFR2 Gene Rear... FGFR2 Gene Tran... | Pemigatinib | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | NCT05913661 | Carcinoma Intrahepatic Ch... Digestive Syste... PD-1 Inhibitor First-line Trea... | Pemigatinib PD-1 Inhibitors | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | NCT05004974 | Advanced Non Sm... | Sintilimab Pemigatinib | 18 Years - | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | NCT03822117 | Solid Tumor Mal... | Pemigatinib | 18 Years - | Incyte Corporation | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | NCT05267106 | Glioblastoma Adult-type Diff... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | NCT06022289 | Solid Tumor FGF Receptor Ge... FGF Amplificati... FGF Receptor Ge... FGF Receptor Ge... | Pemigatinib | 18 Years - | Tianjin Medical University Second Hospital | |
| Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations | NCT04258527 | Solid Tumor | Pemigatinib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | NCT06022289 | Solid Tumor FGF Receptor Ge... FGF Amplificati... FGF Receptor Ge... FGF Receptor Ge... | Pemigatinib | 18 Years - | Tianjin Medical University Second Hospital | |
| A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | NCT05202236 | Gastric and Col... | pemigatinib | 18 Years - | Wuhan Union Hospital, China | |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | NCT04003610 | Metastatic Urot... Unresectable Ur... | Pemigatinib Pembrolizumab Gemcitabine Carboplatin | 18 Years - | Incyte Corporation | |
| Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | NCT05913661 | Carcinoma Intrahepatic Ch... Digestive Syste... PD-1 Inhibitor First-line Trea... | Pemigatinib PD-1 Inhibitors | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer | NCT03906357 | Pemigatinib | - | Incyte Corporation | ||
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | NCT04096417 | FGFR1 Gene Ampl... FGFR1 Gene Muta... FGFR1 Gene Tran... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR2 Gene Tran... FGFR3 Gene Ampl... FGFR3 Gene Muta... FGFR3 Gene Tran... Metastatic Colo... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... | Pemigatinib Quality-of-Life... | 18 Years - | Academic and Community Cancer Research United | |
| Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations | NCT05651672 | Gastrointestina... | Pemigatinib | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer | NCT03906357 | Pemigatinib | - | Incyte Corporation | ||
| Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | NCT06439485 | Advanced Cholan... FGFR2 Fusion | Pemigatinib Atezolizumab Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients | NCT05210946 | Non-Small Cell ... | Pemigatinib | 18 Years - | The First Affiliated Hospital of Soochow University | |
| A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | NCT05202236 | Gastric and Col... | pemigatinib | 18 Years - | Wuhan Union Hospital, China | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | NCT05253807 | Non-Small Cell ... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery | NCT04294277 | Urothelial Canc... | Pemigatinib | 18 Years - | European Association of Urology Research Foundation | |
| A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant | NCT05997459 | Locally Advance... | Pemigatinib | 18 Years - | Sun Yat-sen University | |
| Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | NCT04256980 | Cholangiocarcin... | Pemigatinib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma | NCT06300528 | Recurrent Extra... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Refractory Extr... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Pemigatinib Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | NCT03822117 | Solid Tumor Mal... | Pemigatinib | 18 Years - | Incyte Corporation | |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | NCT02393248 | Lung Cancer Solid Tumor Gastric Cancer Urothelial Canc... Endometrial Can... Multiple Myelom... Myeloproliferat... Breast Cancer Cholangiocarcin... UC MPN | Pemigatinib Gemcitabine Pembrolizumab Docetaxel Trastuzumab Retifanlimab Cisplatin | 18 Years - | Incyte Corporation | |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | NCT04463771 | Endometrial Can... | retifanlimab epacadostat pemigatinib INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
